Topics
October 2016 | Cover Focus: New Developments
5-Year Results With a Retinal Prosthesis System
Patients with severe to profound RP are experiencing promising outcomes with the Argus II.
Lyndon da Cruz, MA, MD, PhD
November 19, 2026
FDA Grants Rare Disease Evidence Principles Designation to NanoRetinal’s NAR-001 for Inherited Retinal Dystrophy
Foundation Fighting Blindness Receives $1 Million Commitment to Advance Gene-Agnostic Retinal Disease Therapies
November 17, 2026
MacuMira Receives CE Mark Certification for Retinal Microcurrent Stimulation Device to Treat Dry AMD
November 16, 2026
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Advancing Retinal Disease Pipeline
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Supported by Zeiss
Free Print Subscription
Email Newsletter
Conference Calendar